XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2025
Stockholders' Equity Note [Abstract]  
Schedule of Preferred Stock Dividend Declaration and Payment
The following table presents cash dividends declared by the Company on its Series B Preferred Stock from January 1, 2024 through September 30, 2025:

Declaration Date Record DatePayment Date
Annual Dividend Rate
Dividend Per Share
August 21, 2025September 4, 2025September 30, 20257.50%$0.46875
May 19, 2025June 4, 2025June 30, 20257.500.46875
February 18, 2025March 4, 2025March 31, 20257.500.46875
November 20, 2024December 3, 2024December 31, 20247.500.46875
August 16, 2024August 30, 2024September 30, 20247.500.46875
May 21, 2024June 5, 2024June 28, 20247.500.46875
February 20, 2024March 5, 2024March 28, 20247.500.46875
Schedule of Cash Dividends on its Preferred Stock and Common Stock
The following table presents cash dividends declared by the Company on its Series C Preferred Stock from January 1, 2024 through September 30, 2025:

Declaration Date Record DatePayment Date
Annual Dividend Rate
Dividend Per Share
September 2, 2025September 4, 2025September 30, 20259.90226%$0.639521
May 19, 2025June 4, 2025June 30, 20259.905780.619110
February 18, 2025March 4, 2025March 31, 20256.500000.406250
November 20, 2024December 3, 2024December 31, 20246.500000.406250
August 16, 2024August 30, 2024September 30, 20246.500000.406250
May 21, 2024June 5, 2024June 28, 20246.500000.406250
February 20, 2024March 5, 2024March 28, 20246.500000.406250
The following table presents cash dividends declared by the Company on its common stock from January 1, 2024 through September 30, 2025:

Declaration Date
Record DatePayment DateDividend Per Share 
September 11, 2025September 30, 2025October 31, 2025$0.36(1)
June 12, 2025June 30, 2025July 31, 20250.36
March 6, 2025March 31, 2025April 30, 20250.36
December 11, 2024December 31, 2024January 31, 20250.35
September 12, 2024September 27, 2024October 31, 20240.35
June 11, 2024June 28, 2024July 31, 20240.35
March 7, 2024March 28, 2024April 30, 20240.35
(1) At September 30, 2025, the Company had accrued dividends and dividend equivalents payable of $37.3 million related to the common stock dividend declared on September 11, 2025.
Schedule of Changes in Balances of each Component of the Entity's AOCI
The following table presents changes in the balances of each component of the Company’s AOCI for the three and nine months ended September 30, 2025:
Three Months Ended September 30, 2025Nine Months Ended September 30, 2025
(In Thousands)Net Unrealized Gain/(Loss) on AFS Securities
Net Unrealized Gain/(Loss) on Financing Agreements (1)
Total AOCI
Net Unrealized Gain/(Loss) on AFS Securities
Net Unrealized Gain/(Loss) on Financing Agreements (1)
Total AOCI
Balance at beginning of period$4,889 $— $4,889 $9,476 $— $9,476 
OCI before reclassifications32 — 32 (4,329)— (4,329)
Amounts reclassified from AOCI(594)— (594)(820)— (820)
Net OCI during the period (2)
(562)— (562)(5,149)— (5,149)
Balance at end of period$4,327 $— $4,327 $4,327 $— $4,327 
(1)Net Unrealized Gain/(Loss) on Financing Agreements at Fair Value due to changes in instrument-specific credit risk.
(2) For further information regarding changes in OCI, see the Company’s consolidated statements of comprehensive income/(loss).
The following table presents changes in the balances of each component of the Company’s AOCI for the three and nine months ended September 30, 2024:
Three Months Ended September 30, 2024Nine Months Ended September 30, 2024
(In Thousands)Net Unrealized Gain/(Loss) on AFS Securities
Net Unrealized Gain/(Loss) on Financing Agreements (1)
Total AOCI
Net Unrealized Gain/(Loss) on AFS Securities
Net Unrealized Gain/(Loss) on Financing Agreements (1)
Total AOCI
Balance at beginning of period$17,652 $— $17,652 $17,698 $— $17,698 
OCI before reclassifications(202)— (202)2,410 — 2,410 
Amounts reclassified from AOCI(7,328)— (7,328)(9,986)— (9,986)
Net OCI during the period (2)
(7,530)— (7,530)(7,576)— (7,576)
Balance at end of period$10,122 $— $10,122 $10,122 $— $10,122 
(1)  Net Unrealized Gain/(Loss) on Financing Agreements at Fair Value due to changes in instrument-specific credit risk.
(2)  For further information regarding changes in OCI, see the Company’s consolidated statements of comprehensive income/(loss).